The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma

Junko Inoue, Masahiro Ikeda, Sumito Shingaki, Kanji Miyazaki, Sosuke Meshitsuka, Yu Abe, Rieko Sekine, Nobuhiro Tsukada, Yutaka Hattori, Kenshi Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138⁺ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138⁺ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75%) patients in the CD138⁺ cells reduced group, median survival time was 25 months after the reduction in CD138⁺ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138⁺ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138⁺ levels. Taking these observations together, it is unclear whether reduction of the number of CD138⁺ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve.

Original languageEnglish
Pages (from-to)2311-2317
Number of pages7
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume56
Issue number11
DOIs
Publication statusPublished - 2015 Nov 1
Externally publishedYes

Fingerprint

Multiple Myeloma
Cell Count
Survival
Drug Resistance
Chromosome Aberrations
Flow Cytometry
Therapeutics
Observation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma. / Inoue, Junko; Ikeda, Masahiro; Shingaki, Sumito; Miyazaki, Kanji; Meshitsuka, Sosuke; Abe, Yu; Sekine, Rieko; Tsukada, Nobuhiro; Hattori, Yutaka; Suzuki, Kenshi.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 56, No. 11, 01.11.2015, p. 2311-2317.

Research output: Contribution to journalArticle

Inoue, J, Ikeda, M, Shingaki, S, Miyazaki, K, Meshitsuka, S, Abe, Y, Sekine, R, Tsukada, N, Hattori, Y & Suzuki, K 2015, 'The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 56, no. 11, pp. 2311-2317. https://doi.org/10.11406/rinketsu.56.2311
Inoue, Junko ; Ikeda, Masahiro ; Shingaki, Sumito ; Miyazaki, Kanji ; Meshitsuka, Sosuke ; Abe, Yu ; Sekine, Rieko ; Tsukada, Nobuhiro ; Hattori, Yutaka ; Suzuki, Kenshi. / The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2015 ; Vol. 56, No. 11. pp. 2311-2317.
@article{ef61673bff60426ea7b4e150a1056a9c,
title = "The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma",
abstract = "CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138⁺ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138⁺ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75{\%}) patients in the CD138⁺ cells reduced group, median survival time was 25 months after the reduction in CD138⁺ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138⁺ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138⁺ levels. Taking these observations together, it is unclear whether reduction of the number of CD138⁺ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve.",
author = "Junko Inoue and Masahiro Ikeda and Sumito Shingaki and Kanji Miyazaki and Sosuke Meshitsuka and Yu Abe and Rieko Sekine and Nobuhiro Tsukada and Yutaka Hattori and Kenshi Suzuki",
year = "2015",
month = "11",
day = "1",
doi = "10.11406/rinketsu.56.2311",
language = "English",
volume = "56",
pages = "2311--2317",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "11",

}

TY - JOUR

T1 - The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma

AU - Inoue, Junko

AU - Ikeda, Masahiro

AU - Shingaki, Sumito

AU - Miyazaki, Kanji

AU - Meshitsuka, Sosuke

AU - Abe, Yu

AU - Sekine, Rieko

AU - Tsukada, Nobuhiro

AU - Hattori, Yutaka

AU - Suzuki, Kenshi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138⁺ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138⁺ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75%) patients in the CD138⁺ cells reduced group, median survival time was 25 months after the reduction in CD138⁺ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138⁺ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138⁺ levels. Taking these observations together, it is unclear whether reduction of the number of CD138⁺ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve.

AB - CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138⁺ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138⁺ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75%) patients in the CD138⁺ cells reduced group, median survival time was 25 months after the reduction in CD138⁺ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138⁺ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138⁺ levels. Taking these observations together, it is unclear whether reduction of the number of CD138⁺ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve.

UR - http://www.scopus.com/inward/record.url?scp=84979844509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979844509&partnerID=8YFLogxK

U2 - 10.11406/rinketsu.56.2311

DO - 10.11406/rinketsu.56.2311

M3 - Article

C2 - 26666717

AN - SCOPUS:84979844509

VL - 56

SP - 2311

EP - 2317

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 11

ER -